The Effect of Mechanical Activation and Lignin Impurities on the Hydrolysis-Dehydration of Cellulose in the Presence of Sibunit-4 Solid Acidic Carbon Catalysts

Исследовано влияние механической активации и примесей лигнина на реакционную способность образцов целлюлозы, выделенных методом гидротропной варки из мискантуса, соломы пшеницы и плодовых оболочек овса, в процессе их гидролиза-дегидратации в присутствии твердых кислотных катализаторов, полученных сульфированием и окислением углеродного материала Сибунит-4. Показано, что активация существенно увеличивает реакционноспособность всех субстратов и выходы целевых продуктов реакции (моносахаридов и фурфуролов). Наличие примесей лигнина приводит к уменьшению выходов продуктов в процессе деполимеризации целлюлозыIn the presence of acidic catalysts based on the Sibunit-4 material the effects of mechanical activation and a lignin impurities on both the reactivity of cellulose and yields of products (monosaccharides and furfurals) being achieved during the hydrolysis of the polysaccharide isolated by hydrotropic cooking of miscanthus, wheat straw, and fruit shells of oats were studied. Activation was shown to significantly increase the reactivity of all substrates and the yields of the target products. Impurities of lignin led to decreasing product yield

The Effect of Ca, Sr, and Ba Chloride Complexes with Dibenzo-18-Crown-6 Ether as Catalysts on the Process Criteria for the Efficiency of Cumene Oxidation (the First Stage in the Chain of Polymer Composite Production)

A study was made on the effect of Ca, Sr, and Ba chloride complexes with dibenzo-18-crown-6 ether as catalysts on the process criteria of the efficiency of industrial cumene oxidation using kinetic modeling. It is the first stage in the process chain of polymer composite production. The kinetic scheme of the process is made of classical reactions of the radical chain mechanism (reactions of initiation, chain propagation, and chain termination), molecular reactions, reactions of formation of intermediate adducts “component of the reaction mixture—catalyst” and their decomposition, as well as reactions that take into account the specifics of the catalyst used: (1) formation of planar catalyst complexes with various substances; (2) formation of acetophenone along the catalytic path; (3) hydration of the intermediate adduct “α-methylstyrene—catalyst” to the required alcohol. It is shown that the kinetic model fully reproduces the experimental time dependencies of the cumene hydroperoxide concentration in the cumene oxidation and cumene hydroperoxide decomposition. Using the kinetic model, computational experiments were carried out, as a result of which the following conclusions were made: (1) among the considered catalysts, the complex of Sr chloride with dibenzo-18-crown-6 ether should be recognized as the best, provided that it is used at temperatures of 393–413 K and an initial concentration < 2 mmol/L; (2) to ensure selectivity comparable to the selectivity of a non-catalytic process, it is necessary to conduct the catalytic process at a lowest possible initial concentration of any of the considered catalysts

The Effect of Metals of the 2nd and 12th Groups on the Productivity and Selectivity of Cumene Oxidation—The First Stage of the Technological Chain for the Production of Polymer Composites

The effect of the process temperature and the initial concentration of Mg, Ca, Sr, Ba, Zn, Cd, and Hg 2-ethylhexanoates as catalysts on the productivity and selectivity of the oxidation stage of cumene is studied in the technological chain for the production of polymer composites from cumene; “production of phenol by cumene method (stage 1 is cumene oxidation to cumene hydroperoxide, stage 2 is decomposition of cumene hydroperoxide into phenol and acetone) → production of precursors from phenol → production of polymers from precursors → production of composites from polymers”. A criterion has been introduced that reflects the productivity of cumene oxidation at the moment of reaching the maximum concentration of cumene hydroperoxide, which takes into account the cumene conversion and selectivity achieved in this case in the shortest possible time using the selectivity comparable with the selectivity of a non-catalytic process. It has been shown that the achievement of the maximum value of this criterion, among all the considered catalysts, is ensured by Mg 2-ethylhexanoate at its relatively low initial concentration (1 mmol/L) under conditions of moderately-high process temperatures (393–413 K)

Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study

Background. Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still unstudied. Estimates of the genetically engineered biologic drugs (GEBD) effects on pneumococcal vaccination results also remain controversial.Objective. The aim of the study was to explore the PCV-13 efficacy in patients with SJIA and who is on treatment with monoclonal antibodies against interleukin 6 receptor (tocilizumab) and interleukin 8 receptor beta (canakinumab).Methods. The study included patients under the age of 18 with SJIA in remission or active form of disease vaccinated with PCV-13. The vaccine was administered in single dose of 0.5 ml intramuscularly in patients on treatment with GEBD or 3 weeks before GEBD administration for the first time (for patients with active disease). Vaccination was considered effective at achievement of the minimum protective level of antibodies to capsular polysaccharide of pneumococcus (anti-SPP IgG; ≥ 7 U/ml) or increase of anti-SPP IgG level ≥ 2 times in 4 weeks after vaccination. The anti-SPP IgG levels were measured with enzyme immunoassay.Results. The study included 53 patients (27 girls) in remission of SJIA and 25 (16 girls) in active disease. Median age was 13.3 and 10.8 years respectively. Tocilizumab/canakinumab was administrated in 43/10 and 18/7 patients respectively. Minimum significant anti-SPP IgG level and two-fold increase in anti-SPP IgG level were recorded in 49/53 (92%) and 32/53 (60%) patients with SJIA in remission, as well as in 22/25 (88%) and 18/25 (72%) patients in active disease respectively. PCV-13 immunological potency in patients with SJIA in remission and in active disease (in those who were initially administrated and who did not receive GEBD) did not differ.Conclusion. PCV-13 vaccination allows to achieve protective antibodies level in most of the patients with SJIA in children population regardless of the disease stage and the history of GEBD administration

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

Abstract: Background: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)\u2013defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). Methods: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. Results: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52\u20131.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. Conclusions: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.Abstract: BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). METHODS: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. RESULTS: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52-1.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. CONCLUSIONS: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs